Topical Omidenepag Isopropyl Lowers Intraocular Pressure in Normal and Glaucomatous Cats: A Pilot Study.

Topical omidenepag isopropyl effectively lowers IOP in normal and glaucomatous cats.

This pilot study evaluated topical omidenepag isopropyl (OMDI), a selective prostaglandin E2 receptor 2 (EP2) agonist, for intraocular pressure (IOP) reduction in cats. The prospective, randomized, placebo-controlled, masked study included 10 cats with feline congenital glaucoma (FCG) and 8 normal cats. Subjects received one drop of 0.002% OMDI in one eye and artificial tears in the contralateral eye, with IOP and pupil diameter measurements recorded at baseline and multiple time points up to 32-36 hours post-administration. Results demonstrated significant IOP reduction in both groups without inducing miosis. Normal cats showed maximum IOP reduction of 7.3 mmHg (43.5%) lasting up to 12 hours, while FCG cats achieved maximum reduction of 16.7 mmHg (60.2%) sustained for 2-8 hours post-instillation. No ocular irritation was observed. These findings suggest topical EP2 agonists represent a promising novel therapeutic option for feline glaucoma management, with results informing appropriate dosing intervals for future investigations.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.